ValuEngine upgraded shares of Ophthotech Corporation (NASDAQ:OPHT) from a hold rating to a buy rating in a research note released on Monday, October 2nd.

Separately, Stifel Nicolaus reiterated a hold rating and set a $4.00 price target on shares of Ophthotech Corporation in a report on Thursday, September 21st. Twelve analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Ophthotech Corporation currently has an average rating of Hold and a consensus target price of $47.33.

Ophthotech Corporation (NASDAQ OPHT) traded up 1.54% on Monday, hitting $2.63. 463,354 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $2.73 and its 200-day moving average price is $2.73. The company’s market cap is $94.53 million. Ophthotech Corporation has a 12-month low of $2.24 and a 12-month high of $40.34.

Ophthotech Corporation (NASDAQ:OPHT) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.45. The business had revenue of $1.66 million for the quarter, compared to analysts’ expectations of $1.38 million. During the same period last year, the firm earned ($0.85) EPS. The company’s revenue was down 94.1% compared to the same quarter last year. Analysts forecast that Ophthotech Corporation will post ($0.24) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Ophthotech Corporation (OPHT) Stock Rating Upgraded by ValuEngine” was originally reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at http://www.mareainformativa.com/ophthotech-corporation-opht-raised-to-buy-at-valuengine/117391/.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning lifted its holdings in shares of Ophthotech Corporation by 4,867.3% during the second quarter. Creative Planning now owns 46,941 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 45,996 shares during the last quarter. Federated Investors Inc. PA lifted its holdings in shares of Ophthotech Corporation by 102.3% during the second quarter. Federated Investors Inc. PA now owns 55,461 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 28,040 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Ophthotech Corporation by 67.7% during the first quarter. SG Americas Securities LLC now owns 50,867 shares of the biopharmaceutical company’s stock worth $186,000 after buying an additional 20,537 shares during the last quarter. Teachers Advisors LLC lifted its holdings in shares of Ophthotech Corporation by 6.1% during the fourth quarter. Teachers Advisors LLC now owns 52,243 shares of the biopharmaceutical company’s stock worth $252,000 after buying an additional 2,999 shares during the last quarter. Finally, LMR Partners LLP acquired a new position in shares of Ophthotech Corporation during the second quarter worth approximately $269,000. Hedge funds and other institutional investors own 61.40% of the company’s stock.

About Ophthotech Corporation

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ophthotech Corporation (NASDAQ:OPHT)

Receive News & Stock Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related stocks with our FREE daily email newsletter.